TOREMIFENE
Breast Carcinoma In Situ
Fred Hutchinson Cancer CenterSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Breast Carcinoma In Situ cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Letrozole Alliance for Clinical Trials in Oncology | Phase 4 | BBB |
EXEMESTANE Alliance for Clinical Trials in Oncology | Phase 4 | BBB |
TAMOXIFEN Alliance for Clinical Trials in Oncology | Phase 4 | BB |
ANASTROZOLE Alliance for Clinical Trials in Oncology | Phase 4 | BB |
Revaree Plus Memorial Sloan Kettering Cancer Center | Phase 4 | BB |
View all 28 →
Same molecule, other indications
TOREMIFENE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →